Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
IPO Year: 2008
Exchange: NASDAQ
Website: atai.life
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/3/2024 | $6.00 | Hold → Buy | Maxim Group |
| 11/1/2022 | $18.00 | Buy | Loop Capital |
| 11/30/2021 | $25.00 | Buy | Maxim Group |
| 11/22/2021 | $40.00 → $50.00 | Buy | HC Wainwright & Co. |
| 11/16/2021 | $25.00 → $24.00 | Outperform | Credit Suisse |
| 11/16/2021 | $19.00 → $17.00 | Sector Perform | RBC Capital |
| 11/11/2021 | $32.00 | Buy | Roth Capital |
| 10/18/2021 | $40.00 | Buy | HC Wainwright & Co. |
| 9/1/2021 | $27.00 | Buy | Jefferies |
| 8/17/2021 | $26.00 → $27.00 | Buy | Aegis Capital |
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
Maxim Group upgraded atai Life Sciences N.V. from Hold to Buy and set a new price target of $6.00
Loop Capital initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $18.00
Maxim Group initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $25.00
HC Wainwright & Co. reiterated coverage of ATAI Life Sciences with a rating of Buy and set a new price target of $50.00 from $40.00 previously
Credit Suisse reiterated coverage of ATAI Life Sciences with a rating of Outperform and set a new price target of $24.00 from $25.00 previously
RBC Capital reiterated coverage of ATAI Life Sciences with a rating of Sector Perform and set a new price target of $17.00 from $19.00 previously
Roth Capital initiated coverage of ATAI Life Sciences with a rating of Buy and set a new price target of $32.00
HC Wainwright & Co. initiated coverage of ATAI Life Sciences with a rating of Buy and set a new price target of $40.00
Jefferies initiated coverage of atai Life Sciences N.V. with a rating of Buy and set a new price target of $27.00
Aegis Capital reiterated coverage of ATAI Life Sciences with a rating of Buy and set a new price target of $27.00 from $26.00 previously
NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company's Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place from October 15 – 17, 2024. Details of the company's participation: Format: Virtual fireside chat Date: Wednesday, October 16, 2024 Presentation Time: 3:30 P.M. EDTWebcast: Register here An archived replay will be available on the Investors section of the atai website under Events for up to 30 days. About at
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company's participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Tuesday, September 10 at 4:30 P.M. EDTWebcast link: Here An archived replay will be available on the Investors section of the atai website under Events for up to 90 days. Ab
• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE'24 • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced second quarter 2024 financial results and pr
VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interventional psychiatryVLS-01 reached peak plasma concentration within 30-45 minutes and was shown to induce a short psychedelic experience, with subjective effects generally resolving within 90-120 minutesVLS-01 demonstrated a favorable safety profile and was well tolerated, with all adverse events classified as either mild or moderate, and most resolving on the day of dosingatai expects to initiate a randomized, double-blind, placebo-controlled Phase 2 study of VLS-01 to assess the efficacy, safety and durability of respon
NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company's participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat on Wednesday August 14 at 11:00 A.M. EDTWebcast link: Here An archived replay will be available on the Investors section of the atai website under Events for up to 90 days. Abou
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company's participation: Format: Virtual fireside chat and 1x1 investor meetingsDate and Time: Fireside chat available on-demand from Thursday, June 27 at 07:00 A.M. ETWebcast link: here An archived replay will be available on the Investors section of the atai website under Events for up to 90 days.
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours.The Phase 2a part of the study will evaluate the safety, tolerability, subjective effects, and efficacy of a single intravenous (IV) dose of ELE-101 in 6-12 participants with Major Depressive Disorder (MDD). Results are expected in H2 2024.The dose for Phase 2a was selected using preliminary pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 1 randomized, double-blind, placebo-controlled, single ascending dose part of the study of ELE-101 in healthy participants,
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024. Details of the company's participation: Format: Fireside ChatDate and Time: Thursday June 6 at 10:00 A.M. ETLocation: New YorkWebcast link: here The live webcast of the fireside chat will also be available on the Investors section of the atai website under Events. A replay will be available following the live event. About atai Life
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H'24; Phase 2 study in TRD patients anticipated to initiate around YE'24Beckley Psytech's Phase 2a study of BPL-003 in TRD patients showed rapid and durable antidepressant effects; Phase 2b topline data expected in 2H'24Compass Pathways' Phase 2 study of COMP360 in PTSD patients demonstrated durable improvement in symptoms; Phase 3 data of COMP360 in TRD patients expected in 4Q'24 Co-Founder Florian Brand to step down as CEO as part of a planned transition by YE'24 and to be succeeded by Co-Founder and current Chief Scientific Officer Srinivas Rao, M.D., Ph.D. Cash, marketable securities, and committed term loan fundi
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Reporting)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
4 - ATAI Life Sciences N.V. (0001840904) (Issuer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
10-Q - ATAI Life Sciences N.V. (0001840904) (Filer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
10-Q - ATAI Life Sciences N.V. (0001840904) (Filer)
8-K - ATAI Life Sciences N.V. (0001840904) (Filer)
DEF 14A - ATAI Life Sciences N.V. (0001840904) (Filer)
PRE 14A - ATAI Life Sciences N.V. (0001840904) (Filer)
Strategic investment in Beckley Psytech reinforces atai's position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai's existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatment Resistant Depression in 2H24 BPL-003 has the potential to become a first-in-class short-duration psychedelic treatment with rapid acting and durable antidepressant effects Anticipated synergies th
– Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment associated with schizophrenia (CIAS), clinical trial initiations with PCN-101, GRX-917 and DMX-1002, and successful completion of 2 cohorts in the Introspect Digital Therapeutics ketamine trials – Eight new programs added to platform since January 2021 bringing total, as of today, to 13 discovery and drug development programs and four enabling technologies – Ended 2021 very well capitalized with $362 million to execute our strategy to achieve clinically meaningful and sustai
NEW YORK and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a webcast on Wednesday, March 30, 2022 at 8:30 a.m. ET to discuss its financial results for the fourth quarter 2021 and provide a business update. To access the webcast, please log in at https://wsw.com/webcast/cc/atai/1358298. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life. About atai Life Sciences atai was founded in 2018 as a response to the significant
-Positive topline results from COMP360's Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress across 11 therapeutic programs, including initiation of Perception's Phase 2a and DemeRx's Phase 1/2 trials as well as interim Phase 2a RL-007 readout of first cohort- -Launch of atai Impact, a philanthropic program to harness the power of innovative mental health approaches for social change- -Company to host a webcast and conference call today at 08:30am EST- BERLIN and NEW YORK, Nov. 15, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company ai
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, November 15, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update. To access the live conference call, please dial 877-407-3982 from the United States, or +1 (201) 493-6780 internationally, using the conference ID: 13724750. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life.
BERLIN, Aug. 09, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ:ATAI) ("atai"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it plans to host a conference call on Monday, August 16, 2021 at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and provide a business update. To access the live conference call, please dial 877-407-3982 from the United States, or +1 (201) 493-6780 internationally, using the conference ID: 13721888. The live and archived webcast of this call will be available in the "Events" section of the atai Life Sciences website at ir.atai.life. Abou
Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.
ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours. The Phase 2a part of the study will evaluate the safety, tolerability, subjective effects, and efficacy of a single intravenous (IV) dose of ELE-101 in 6-12 participants with Major Depressive Disorder (MDD). Results are expected in H2 2024. The dose for Phase 2a was selected using preliminary pharmacokinetic (PK) and pharmacodynamic (PD) data from the Phase 1 randomized, double-blind, placebo-controlled, single ascending dose part of the study of ELE-101 in healthy particip
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.Some members of the panel, like sociologist Elizabeth Joniak-Grant, pointed to allegations of misconduct in trials th
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD). The Details: MindMed and other psychedelic stocks, including ATAI Life Sciences N.V (NASDAQ:ATAI) and COMPASS Pathways Plc (NASDAQ:CMPS), are down after an FDA panel rejected the use of MDMA-assisted therapy for PTSD on Tuesday. The FDA panel voted 9 to 2 on whether the MDMA-assisted therapy was effective and 10 to 1 on whether the proposed treatment's benefits outweighed its risks. Members of the panel expressed concerns about the designs of the two studies submitte
HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 price target.
ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 19.05 percent increase over losses of $(0.21) per share from the same period last year.
Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:KAYS) has been awarded a license by the Oregon Health Authority to operate a Psilocybin Service Center. Oregon is the only state in the US that has developed a licensing framework that allows for the administration of psilocybin in a safe and legal setting under the guidance of State Licensed Facilitators. KAYS through its Fifth Dimension Therapeutics, Inc. subsidiary, plans to operate The Sacred Mushroom, a full-service psychedelic treatment center that will allow clients to receive psilocybin treatment in a setting offering significant experience differentiators and concept innovations. The Sacred Mushroom expects to s
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings The Drug Enforcement Administration (DEA) is revisiting its stance on the classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). The agency has proposed both be listed as Schedule I substances under the Controlled Substances Act (CSA). If added to the Schedule I list, these compounds would be officially considered as having high abuse potential with no recognized medical use. The evaluation is being disputed by experts. Three formal requests for a hearing were submitted, prompting a reconsideration by the agency.
atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech's novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychopharmacology. The double-blind, placebo-controlled, single ascending dose Phase 1 study explored the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003 in combination with psychological support in 44 psychedelic-naïve healthy volunteers. Participants across seven cohorts were given either a single dose of BPL-003 between 1 mg to
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai's supervisory board ("Board") subject to applicable legal requirements. Scott Braunstein, M.D., is the Chief Executive Officer ("CEO") and Chairman of Marinus Pharmaceuticals, Inc. He is an operating partner at Aisling Capital and serves on the Board of Directors at both Caribou Biosciences, Inc. and Trevena Inc. Previously, Dr. Braunstein was Chief Operati
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company") today announced that Anne Johnson, the Company's interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company's CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. "Anne has been an integral member of our team for over three years and has demonstrated the executive leadership, financial acumen, and track record to lead our financial organization with excellence," said atai Co-founder and Chief Executive Off
Cognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor relations functions at the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017630946/en/Greg Weaver, CFO, Cognito Therapeutics (Photo: Business Wire) Mr. Weaver is a highly accomplished finance executive who brings more than 30 years of life sciences, financial and operations experience to Cognito. Most recently, he served as CFO of Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage oncology comp
SEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces the appointment of Greg Weaver as the Company's new Chief Financial Officer (CFO). Mr. Weaver succeeds Kyle Guse. A short video interview with Mr. Weaver about his background and vision for Atossa can be found here: https://youtu.be/G6ZzHLh-qsQ Mr. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commerc
- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee - - He has spent more than 15 years building and growing organizations and businesses in the life sciences and digital health industries - - His deal sheet includes transactions totaling more than USD 2.7 billion in CNS and beyond - NEW YORK and BERLIN, Nov. 29, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V., (NASDAQ:ATAI) ("atai" or the "Company"), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced today its appointment of Dr. Kirpekar to serve as the Company's Chief Busines
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of "magic" mushrooms can be used to treat depression. Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. According to CAMH's lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce "sustained antidepressant effects" in individuals living with severe depression. This news comes just days after a major scientific review found "no clear evidence
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Kures Therapeutics, Inc ("Kures"), an atai Life Sciences N.V. (NASDAQ:ATAI) ("atai") company focused on developing treatment options to better manage addictions, depression, and pain, today announced the appointment of Chad E. Beyer, Ph.D., MBA, currently Senior Vice President of Research and Development at Promentis Pharmaceuticals, Inc ("Promentis"), as Chief Executive Officer of Kures, effective July 1, 2022. Dr. Beyer has over 25 years of experience in the discovery, research and translational development of medications that treat the central nervous system and neurological disorders. He has led several preclinical and clinical drug discove
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13G/A - ATAI Life Sciences N.V. (0001840904) (Subject)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13G/A - ATAI Life Sciences N.V. (0001840904) (Subject)
SC 13G - ATAI Life Sciences N.V. (0001840904) (Subject)
SC 13G - ATAI Life Sciences N.V. (0001840904) (Subject)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)
SC 13D/A - ATAI Life Sciences N.V. (0001840904) (Filed by)